6-K 1 d279962d6k.htm FORM 6-K Form 6-K
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month ended November 30, 2016

Commission File Number 0-28564

 

 

QIAGEN N.V.

 

 

Hulsterweg 82

5912 PL Venlo

The Netherlands

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T

Rule 101(b)(1):  ☐

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T

Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 

Table of Contents

QIAGEN N.V.

Form 6-K

TABLE OF CONTENTS

 

Item

    Page  

Other Information

      3   

Signatures

      4   

Exhibit Index

      5   

 

2

Table of Contents

OTHER INFORMATION

On November 15, 2016, QIAGEN N.V. held an Analyst & Investor Day in New York, New York. The presentations discussed that day are furnished herewith as Exhibit 99.1 through 99.9 and are incorporated by reference herein.

USE OF NON-GAAP FINANCIAL MEASURES

QIAGEN reports adjusted results, as well as results on a constant exchange rate basis, and other non-U.S. GAAP (generally accepted accounting principles) figures, to provide additional insight on performance. Adjusted results included in the Exhibits reflect adjusted operating expenses, adjusted earnings interest, taxes, depreciation and amortization (EBITDA), adjusted diluted earnings per share and free cash flow. Adjusted results are non-GAAP financial measures that we believe should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. We believe certain items should be excluded from adjusted results when they are outside of our ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the appendices provided in the Exhibits entitled “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. We do not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on our GAAP results.

FORWARD-LOOKING STATEMENTS

Exhibits 99.1 through 99.9 contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, goals, strategy and financial and operational outlook. These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for our products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting our products to integrated solutions and producing such products; our ability to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of our new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that we have filed with, or furnished to, the U.S. Securities and Exchange Commission. We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

 

3

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

 

By:  

/s/ Roland Sackers

  Roland Sackers
  Chief Financial Officer
Date:   November 23, 2016

 

4

Table of Contents

EXHIBIT INDEX

 

Exhibit

No.

   

Exhibit

99.1    Introduction 2016 Analyst & Investor Day
99.2    Strategy Update
99.3    Life Sciences
99.4    Molecular Diagnostics
99.5    Bioinformatics
99.6    Commercial Operations
99.7    Finance
99.8    QuantiFeron-TB
99.9    GeneReader NGS System

 

5

Table of Contents

Exhibit 99.1

LOGO

 

QIAGEN

Welcome:

2016 Analyst & Investor Day

John Gilardi

Vice President, Corporate Communications and Investor Relations November 15, 2016

Sample to Insight

2016 Analyst & Investor Day

Table of Contents

LOGO

 

QIAGEN

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

Table of Contents

LOGO

 

QIAGEN

10:30 – 10:40 Introduction John Gilardi

Vice President, Corporate Communications and Investor 10:40 – 11:10 Strategy update Peer M. Schatz Chief Executive Officer 11:10 – 11:25 Life Sciences Brad Crutchfield Senior Vice President, Life Sciences Business Area 11:25 – 11:40 Molecular Diagnostics Thierry Bernard Senior Vice President, Molecular Diagnostics Business Area 11:40 – 11:55 Bioinformatics Dr. Laura Furmanski Senior Vice President, Bioinformatics Business Area 11:55 – 12:05 Break 12:05 – 12:20 Commercial Operations Manuel O. Méndez Senior Vice President, Global Commercial Operations 12:20 – 12:40 Finance Roland Sackers Chief Financial Officer 12:40 – 13:00 Q&A session EC members 13:00 – 13:30 Lunch break with QIAGEN management 13:30 – 13:50 QuantiFERON-TB Dr. L. Masae Kawamura, M.D.

Senior Director, Medical & Scientific Affairs, TB Diagnostics, Molecular Diagnostics Business Area 13:50 – 14:00 Q&A session 14:00 – 14:20 GeneReader NGS System Jonathan Arnold Senior Director, Oncology Business Area Franchise, Molecular Diagnostics Business Area 14:20 – 14:30 Q&A session 14:30 – 14:35 Closing remarks Peer M. Schatz Chief Executive Officer 14:35 – 15:30 Post-event reception

Sample to Insight    

2016 Analyst & Investor Day    

Table of Contents

Exhibit 99.2

LOGO

 

QIAGEN

Setting a new trajectory for growth and greater value creation

Peer M. Schatz

Chief Executive Officer

November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Table of Contents

LOGO

 

QIAGEN

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day 2

Table of Contents

LOGO

 

~60-70%

Market share in Sample Technologies

19,000

Publications mentioning QIAGEN per year

>16

Master Collaboration Agreements

~5,000 kits shipped each day

~50,000

Samples processed each day

Nasdaq

One of the first European companies to be listed on NASDAQ

4,600 employees

Sample to Insight

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

~$1.3 billion     ConsumablesEurope /Americas

>500,000     (incl. bioinformatics)Middle East /

~87%    Africa

>35 countries     ~32%

~4,600    

    ~47%

NASDAQ / Frankfurt    

Venlo (Netherlands)    

    ~20%

~13%    

    Instruments andAsia-Pacific /

    automation systemsJapan / Rest of world

Situation

QIAGEN at a glance

2015 sales by customer class

Leader in molecular testing solutions

True hybrid covering continuum from Life Sciences to Molecular Diagnostics

Core capabilities

Consumables

Instruments

Automation systems

Facts and figures

    Applied

Academia    Pharma Molecular Diagnostics

    Testing

~22%    ~20% ~9%~49%

2015 sales by product type and region

2015 sales

Customers

Global reach

Employees

Listing

Headquarter

World leader in molecular testing solutions that provide valuable insights

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

Situation

Customers want meaningful molecular insights

Faster Better More efficiently

Sample Technologies Assay Technologies

Bioinformatics Automation systems

VALUABLE

BIOLOGICAL SAMPLE TO INSIGHT SOLUTIONS MOLECULAR

SAMPLE INSIGHTS

Moving from tools and components to solutions that provide valuable insights

Sample to Insight

2016 Analyst & Investor Day 5

Table of Contents

LOGO

 

Situation

Create a molecular franchise

$50 $45 $40

$35

$19.85

$30 $17.11 $25

$20

$15

$10

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 +

Transformation has begun to create value – but took longer than expected

Sample to Insight

2016 Analyst & Investor Day 6

Table of Contents

LOGO

 

$50 $45 $40

$35

$19.85

$30 $17.11

$14.16 $25

$20

$15

$10

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 +

Transformation has begun to create value – but took longer than expected

Sample to Insight

2016 Analyst & Investor Day 7

Situation

Create a molecular    Significant

franchise    reorganization

Table of Contents

LOGO

 

$50 $45 $40

$23.37 $35

$19.85

$30 $17.11

$14.16 $25

$20

$15

$10

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 +

Transformation has begun to create value – but took longer than expected

Sample to Insight

2016 Analyst & Investor Day 8

Situation

Create a molecular    Significant Portfolio

franchise    reorganization transformation

Table of Contents

LOGO

 

$50

$45

$40 $27.51

$23.37 $35

$19.85

$30 $17.11

$14.16 $25

$20

$15

$10

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 +

Transformation has begun to create value – but took longer than expected

Situation

Create a molecular    Significant PortfolioCommercial

franchise    reorganization transformationacceleration

Note: Latest share price as of November 11, 2016.

Sample to Insight

2016 Analyst & Investor Day 9

Table of Contents

LOGO

 

$50

$45

$40 $27.51

$23.37 $35

$19.85

$30 $17.11

$14.16 $25

$20

$15

$10

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 +

Transformation has begun to create value – but took longer than expected

Situation

Create a molecular    Significant PortfolioCommercialSustain growth

franchise    reorganization transformationaccelerationand deliver value

Note: Latest share price as of November 11, 2016.

Sample to Insight

2016 Analyst & Investor Day 10

Table of Contents

LOGO

 

QIAGEN sales evolution    

Create a molecular    Significant PortfolioCommercialSustain growth

franchise    reorganization transformationaccelerationand deliver value

$1.30 bn $1.33 bn $1.28 bn

$1.25 bn

$1.17 bn ~6% ~3%

$1.09 bn ~10%

~13% ~94% ~97%

$1.01 bn ~15%

~90%

~17% ~87%

~20% ~85% ~83%

~80% ?12% CER

~28% ~27%

~25% EPS CAGR

~23% ~23%

target

~18%

~15%

2009 2010 2011 2012 2013 2014 2015 2016 2020+

Sales excl. U.S. HPV U.S. HPV sales Adj. operating income margin

U.S. HPV sales headwinds obscured QIAGEN’s fundamental progress

Note: QIAGEN announced a new adjustment policy as of January 1, 2014, to no longer adjust for share-based compensation and non-M&A related restructuring Sample to Insight charges, but to continue adjusting for M&A-related expenses. Data shown applies the policy retrospectively to 2009-2013.

2016 Analyst & Investor Day 11

Situation

Table of Contents

LOGO

 

Situation

Selected QIAGEN M&A transactions    Selected acquisitions since 2008

    EV(1)

Date    Target ($ m)Strategic valueNGS and bioinformatics

March 2016    Exiqon 101RNA analysis technologiesIntelligent Bio-Systems

Dec 2015    MO BIO 67Microbial sample technologiesCLC Bio

    Ingenuity

Jan 2015    Enzymatics 100NGS enzymes solutionsBiobase

Aug 2013    CLC Bio 68Secondary genomic data analysisEnzymatics

April 2013    Ingenuity 105Tertiary genomic data analysisPersonalized Healthcare

May 2012    AmniSure 101Women’s health test, fit with HPV salesDxS

April 2012    IBS 31Access to NGS sequencing technologyIpsogen

June 2011    Ipsogen 101Hematology tests on QIAsymphonyBlockbuster potential

April 2011    Cellestis 355QuantiFERON technology and TB blockbuster

    Cellestis (QuantiFERON)

Jan 2010    ESE 19Portable testing platform

Nov 2009    SABiosciences 90Biological content for PCR and NGSAdditions to core technologies

Sept 2009    DxS 95Solid cancer tumor tests on QIAsymphonyMO BIO

    Exiqon

July 2008    Corbett 70Rotor-Gene PCR integration with QIAsymphonyCorbett (PCR)

June 2007    Digene 1,500HPV blockbuster to create molecular franchiseSABiosciences

Transformation was the right decision to create a stronger QIAGEN

Source: Company filings.

(1) Excluding milestone payments and other contingencies

Sample to Insight

2016 Analyst & Investor Day 12

Table of Contents

LOGO

 

Brad Thierry Crutchfield Bernard

Scientific Better and Secure Better

Examples: breakthroughs safer drugs and protect healthcare

Blood #1 Liquid biopsy #1 Sample Technologies Tissue #1 Other #1

PCR #3 Automation Assay NGS New Technologies QuantiFERON #1 Other Software and Biox #1 biological content

Life sciences Pharma Human ID / Infectious Immune Oncology research R&D Food / Vet diseases monitoring

Laura

Furmanski Key applications

Current Future

PCR – Polymerase Chain Reaction NGS – Next-generation sequencing Other – Includes Hybrid Capture and ModaPlex Biox – Bioinformatics

Opportunity

Customers

Life Sciences Molecular Diagnostics

Manuel O.

Méndez Academia Pharma Applied Testing Clinical Healthcare

Sample to Insight

2016 Analyst & Investor Day 13

Table of Contents

LOGO

 

Opportunity

AMP 2016: Early movers on new trends in Molecular Diagnostics

Sample to Insight

2016 Analyst & Investor Day 14

Table of Contents

LOGO

 

    Analyst & Investor Day:

    November 2013

Sales     Improving trends while addressing challenges

targets     Reallocating resources to best opportunities

Growth     Building momentum

drivers     QIAsymphony

    Personalized Healthcare (PHC)

    QuantiFERON-TB

    Bioinformatics

    Next-generation sequencing

Operating     Further improve operating margin

efficiency     Significant operational improvements

Capital     More leverage with healthy financial position

structure     Completed first $100 m buyback,

    new program started

M&A     Continue consistent M&A strategy

Reviewing our progress since 2013

Sample to Insight

2016 Analyst & Investor Day

Opportunity

15

Table of Contents

LOGO

 

Strategy

Maximize sales growth

Ongoing expansion of Sample to Insight portfolio

Deliver operating leverage

Sustain strong sales growth while improving leverage

Optimize balance sheet

Maximize value of cash flows and increase returns

Develop our organization

Commitment of Board and EC to creating value

Strategy: Setting a new trajectory for growth and greater value creation

Sample to Insight

2016 Analyst & Investor Day 16

Table of Contents

LOGO

 

Strategy

Academia    Pharma Applied TestingMolecular Diagnostics

Scientific breakthroughs    Better and safer drugs Secure and protectBetter healthcare

QIAGEN    

addressable    ~$3 billion ~$1 billion~$0.5 billion~$3-4 billion

market    

Annual    ~+3% overall ~-5% basic research~+8-12%+7-10%

market growth    >+5% clinical research +10% clinical research

    >80% of all QIAGENproducts are

    sold to more than one customer class

Addressing ~$8-9 billion market opportunity with our Sample to Insight portfolio

Sample to Insight

2016 Analyst & Investor Day

17

Table of Contents

LOGO

 

    Strategy

Key highlight areas: QIAGEN’s Sample to Insight portfolio    

    LifeMolecular

    SciencesDiagnostics

QuantiFERON    

Universal NGS solutions and    

GeneReader NGS System    

Powered by    

QIAGEN    Personalized Healthcare

Bioinformatics    

QIAsymphony    

Differentiated Technologies    

Applications including:    

?    Single-cell research

?    Liquid biopsy

?    Microbiome

?    Epigenetics

Growth opportunity around Sample to Insight portfolio    

Sample to Insight    

2016 Analyst & Investor Day    18

Table of Contents

LOGO

 

Strategy

QuantiFERON

Opportunity

QuantiFERON: “Pre-molecular” technology

Lead $1 billion latent TB test market conversion

Attractive menu expansion options

Trends

Clinical needs for latent and active disease detection

Global push for TB prevention and elimination

2016 developments

2016 goal: >$140 million of QuantiFERON-TB sales

Ongoing conversion from tuberculin skin test (TST)

Support from new TB guidelines (USPSTF)

QFT-Plus 4th generation test:

CE-IVD launch momentum

U.S. submission in Q4 2016

Fully addressed issues in U.S. FDA warning letter

QIAGEN value proposition    2017-2020 ambitions

QuantiFERON-TB: Modern gold standard TB test    2020 target: >$300 million of QuantiFERON-TB sales

QuantiFERON Monitor and CMV tests (CE-IVD)    Advance TB detection with QFT-Plus clinical benefits

Scalable automation solutions    Expand QuantiFERON to other latent diseases

QuantiFERON: Setting new standards in the global fight against TB

Sample to Insight

2016 Analyst & Investor Day

19

Table of Contents

LOGO

 

Strategy

Next-generation sequencing

Opportunity

Increasing demand for universal NGS solutions

Shape emergence of oncology benchtop sequencing ? >$200 m market with dynamic potential

Trends

NGS a standardized technology in Life Sciences

Unique MDx customer needs restricting adoption

Increasing clinical value from multi-gene analysis

QIAGEN value proposition

GeneReader NGS System – Sample to Insight

Deep solution portfolio across NGS value chain

Complementary portfolios (e.g. PCR)

2016 developments

2016 target: >$100 m of universal NGS solution sales

GeneReader NGS System:

2016 target: ~55-60 placements with >10% share

Returning to U.S. market with new chemistry

Delivering on new content and features

2017-2020 ambitions

GeneReader NGS System

Goal: >20% share of oncology benchtop sequencing

Expand to other clinical and research areas

Universal NGS solutions

Above-market growth and share gains

Innovation leader with new workflow solutions

GeneReader: Driving adoption of NGS technology in clinical applications

Sample to Insight

2016 Analyst & Investor Day

20

Table of Contents

LOGO

 

Strategy

Personalized Healthcare    

Opportunity    2016 developments

Precision medicine changing cancer treatment    Milestone: >16 master collaboration agreements in 2016

Scientific advances: New tests and technologies    Two new collaborations

    Daiichi Sankyo – new extensive collaboration

Trends     Confidential partner – immuno-oncology therapies

    Expanded portfolio with GeneReader NGS System

Significant growth in molecular testing (PCR and NGS)    Only supplier offering PCR and NGS technologies

Increasing acceptance of CDx value    2017-2020 ambitions

Varying regulatory conditions worldwide    

QIAGEN value proposition     Ambition to capture >50% of all CDx partnering deals

    Expand CDx test portfolio to labs worldwide:

No. 1 worldwide in molecular companion diagnostics    PCR

No. 1 in pharma co-development collaborations    NGS

Proven track record of CE-IVD and FDA approvals    Other molecular technologies

Personalized Healthcare: Expanding our leadership with NGS solutions

Sample to Insight

2016 Analyst & Investor Day

21

Table of Contents

LOGO

 

Strategy

QIAsymphony    

Opportunity    2016 developments

Medium-throughput testing: >$750 m market    On track for >1,750 cumulative placements in 2016

Customer demand for robust automation systems    Front-end use with GeneReader NGS System

? Modular components for different applications    Workflow automation of QIAGEN liquid biopsy kits

Trends     Major tender wins (viral load and transplantation)

Increasing test volumes requires more automation    

Both IVD and laboratory-developed tests increasing    2017-2020 ambitions

    2017 goal: >2,000 cumulative placements

QIAGEN value proposition     Geographic strategy:

QIAsymphony: Highly flexible, proven automation    Europe and rest of world: Broaden test menu

Largest IVD test menu in Europe    U.S.: Address LDT and sample processing demand

Standard for sample processing for any application    

QIAsymphony: Highly versatile automation solution providing solid growth

Sample to Insight    

2016 Analyst & Investor Day    22

Table of Contents

LOGO

 

Strategy

Differentiated Technologies

Opportunity

Improving Life Sciences funding trends

Demands for workflow solutions – not technologies

Trends

Cycle of scientific breakthroughs gaining momentum

Faster transition into clinical applications (IVD / LDT)

2016 developments

Developing Sample to Insight workflows:

Liquid biopsy

Digital NGS

Microbiomes

Epigenetics

Single-cell research

More to come

QIAGEN value proposition    2017-2020 ambitions

Sample to Insight solutions    Expand portfolio by at least 2 emerging technologies

Trusted brand    per year

Ability to standardize and support breakthroughs    Drive double-digit CER sales growth

[Graphic Appears Here]

Differentiated Technologies: Turning innovations into attractive workflows

Sample to Insight

2016 Analyst & Investor Day

23

Table of Contents

LOGO

 

Strategy

Bioinformatics

100% hardware Software + Integration 100% software

TACGT ATGCA

Hardware drives technology Appreciation for hardware Software drives technology adoption, with software in a and software roles to create adoption with focus on secondary role fully integrated solutions universal solutions

Bioinformatics: Winning as standalone as well as integrated solutions

Sample to Insight

2016 Analyst & Investor Day 24

Table of Contents

LOGO

 

Strategy

QIAGEN sales trends (CER)

9%

7%    

6%

5%    

5% 5%    

4% 4%    

3% 3% 4%    3%

2%    2%

2%

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2    Q3 Q4 Q1 Q2 Q3

2013 2013 2013 2013 2014 2014 2014 2014 2015 2015 2015 2015 2016 2016 2016

Operating expenses vs. gross margin

Portfolio rejuvenation

(3-year CER sales CAGR of 2013 portfolio, excluding M&A)

2013     2016E

24%    

    ~40%

76%     ~60%

<10% CER growth    

>10% CER growth    

Adjusted operating expenses(1)    

(As % of net sales)    

48%     ~46-47%

47%    47% 49%CER~44-45%

    CER

2013    201420159M 201620162017

    guidancetarget

Sample to Insight    (1) 2016 and 2017 figures are estimates before restructuring charge and at constant exchange rates (CER) for comparator year

2016 Analyst & Investor Day    25

Table of Contents

LOGO

 

Key efficiency initiatives

1

Sales channel optimization Simplify some organizational structures

2

Site consolidation

Focus on

3 growth opportunities Business Service Centers

4

Further enhance Portfolio management performance culture

Initiatives under way to sustain sales growth momentum while creating leverage

Sample to Insight

2016 Analyst & Investor Day 26

Table of Contents

LOGO

 

Strategy

Disciplined capital allocation

Reinvest for organic growth    Increase returns Targeted M&A / licensing

Capture more value from our    Commitment to return $300Continuing our strategy

Sample to Insight portfolio    million by end of 2017Novel technologies

    New productsFuture repurchase optionsMolecular test content

    Geographic expansionunder considerationGeographic expansion

Supporting our business expansion while increasing returns to shareholders

Sample to Insight

2016 Analyst & Investor Day

27

Table of Contents

LOGO

 

    Strategy

Supervisory Board overview    

Board tenure (In years)    Current Supervisory Board members

Prof. Dr. Detlev Riesner    

Manfred Karobath, M.D.    

Erik Hornaess    Joined 2000

Dr. Manfred Karobath    

Dr. Metin Colpan    

Stéphane Bancel    Metin Colpan, Ph.D.

Dr. Werner Brandt    Joined 2013 Joined 2004

Heino von Prondzynski    

Elizabeth Tallett    

Lawrence Rosen    

Stéphane Bancel    

Dr. Elaine Mardis    

Dr. James Bradner    

Dr. Ross Levine    

94 96 98 00    02 04 06 08 10 121416

Former members    Current members

Elaine Mardis, Ph.D.    Ross Levine, M.D.

Joined 2014    Joined 2016

Lawrence A. Rosen    Elizabeth E. Tallett

Joined 2013    Joined 2011

Deep experience and international diversity among Supervisory Board members

Sample to Insight Bradner – Conflict (joined Novartis EC)     Brandt – Tenure at QIAGEN, other mandates     Riesner, Hornaess and von Prondzynski – Retirement

2016 Analyst & Investor Day 28

Table of Contents

LOGO

 

Strategy    

    CEO

Peer    

    Schatz

New members since 2014    

Molecular    LifeBio-

Diagnostics    Sciencesinformatics

Thierry    BradLaura

Committee    Bernard CrutchfieldFurmanski

Commercial    

    Operations

Operations    

Executive    DouglasManuel O.

    LiuMéndez

HR / Corp.    

    CFO

Strategy    

    RolandThomas

    SackersSchweins

Business    

    Development

Jean-Pascal    

    Business Development

Viola    

Solid leadership team with industry experience and    an effectivestructure

(1) Business Development is a strategic function reporting directly to CEO, but not included in EC.    

    Sample to Insight

    2016 Analyst & Investor Day29

Table of Contents

LOGO

 

Strategy

Committed employees worldwide helping customers to gain valuable insights

Sample to Insight

2016 Analyst & Investor Day 30

Table of Contents

LOGO

 

Payoff

Strong governance and top talent

Maximize sales growth

Multiple Deliver operating leverage Value drivers creation Optimize balance sheet

Adjusted EPS growth and capital returns

Opportunity for near-term value creation on delivery of 2017-2020 goals

Sample to Insight

2016 Analyst & Investor Day 31

Table of Contents

LOGO

 

Summary

Reaccelerating performance after transformation Sustainable sales growth and leverage trajectory Emerging as a stronger, focused, differentiated leader Committed to higher returns and greater value creation

Sample to Insight

2016 Analyst & Investor Day 32

Table of Contents

Exhibit 99.3

LOGO

 

Life Sciences:

Innovator at the leading edge of research

Brad Crutchfield

Senior Vice President, Head of Life Sciences Business Areas November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Table of Contents

LOGO

 

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Sample to Insight

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

Life Sciences     Copenhagen,

    Denmark

Brad Crutchfield    

Senior Vice President,    

Business Area Life Sciences    

Joined QIAGEN in 2015    

2015 total sales: ~$644 million    Redwood City,

    California

Life Sciences employees: ~400    

    San Diego,

    California

    Frederick,Hilden,Beijing,

    MarylandGermanyChina

Addressable market    Opportunity AdvantagesValue proposition

    Comprehensive portfolio Distributed discovery Unparalleled customer

    providing workflows thatover highly fundedconfidence

~20%     generate insightsresearch programs

share     Portfolio at the leading

     Standardization to allowedge of discovery

    for wider adoption

~$4 billion    

Recognized innovator supporting breakthroughs in Life Sciences

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

Offers technology support in    Build their own workflows by pulling

response to customer request    components from various vendors

and seek technology support

Supplier Customer

Components catalogue    Challenges

    Sample technology kits Complexity and cost

    Assay systems Biology vs. technology

    Instruments Experimental iteration

    Bioinformatics software Relevance and validation

    Other lab equipment Speed in getting results

Insights valued over the process

Sample to Insight

2016 Analyst & Investor Day

5

Table of Contents

LOGO

 

QIAGEN supports customers with    Customers create their own ecosystem

Sample to Insight solutions    to drive discovery process

Sample    Assay

Technologies    Technologies

Automation systems    

Bioinformatics    

    Customer

BIOLOGICAL SAMPLE TO INSIGHT    VALUABLE

SAMPLE     MOLECULAR

    INSIGHTS

Our ambition: QIAGEN, the leader at creating solutions that drive insights

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

    Foundation for growth

    Leverage emerging applications

    Win at the bench

    Relevant workflows create differentiation

    Inspire discovery

    Empowered to ask increasingly complex questions

Strategy:    Offer SampletoInsight workflows at leading edges of discovery

Sample to Insight

2016 Analyst & Investor Day

7

Table of Contents

LOGO

 

    Single-cell

Liquid biopsy    MicrobiomeHuman ID / Forensics

    research

~$200    ~$100~$150~$350

million    millionmillionmillion

opportunity    opportunityopportunityopportunity

    Cells

Sample Technologies    Cells CellsCellsBlood

Blood    EnvironmentalTissueEnvironmental

PCR    PCRPCRPCR

Assay Technologies    NGS NGSNGSNGS

Digital NGS    Digital NGSDigital NGSDigital NGS

RNA-seq Explorer    RNA-seq ExplorerRNA-seq ExplorerCLC Bio

Bioinformatics    IPA Microbial GenomicsCLC BioQIAGEN KB

HGMD    IPAIPAOther

Other    OtherOther

QIAsymphony    QIAsymphonyQIAsymphonyQIAsymphony

Automation    QIAcube QIAcubeQIAcubeQIAcube

EZ1    EZ1EZ1EZ1

Other    OtherOtherOther

Capturing opportunities by creating differentiated Sample to Insight workflows

Sample to Insight

2016 Analyst & Investor Day

8

Table of Contents

LOGO

 

Case study: Digital NGS enabled by QIAGEN’s proprietary molecular index technology

Molecular     Tagging gene transcripts prior to amplification

barcoding     Identifying and counting unique transcripts

Single primer     No restrictions of two-target primer design

extension     Uniform PCR reactions without amplification bias

Single pool     Reducing RNA / DNA input needed per sample

of primers    

QIAseq Targeted RNA / DNA Panels    Key application areas

    Platform

Sample    Target LibraryagnosticBio-

processing    enrichment preparationinformatics

    GeneReader

Detection of low frequency variants

Detection of unknown gene fusions

Quantitative gene expression analysis

Digital NGS: Unequalled sensitivity in highly accessible platform-agnostic format

Sample to Insight

2016 Analyst & Investor Day

9

Table of Contents

LOGO

 

Case study: Liquid biopsy    Technology focus areas

    CirculatingExosomesFree circulating

    tumor cellsnucleic acids

~$200 million    (DNA)(DNA / RNA)(DNA / RNA)

opportunity    

    Most comprehensive liquid biopsy portfolio

    Concept first published in a 1947 scientific article

    Non-invasive alternative to a tissue sample PCR

    LiquidQIAampBioX

    Molecular insights from blood or fluids biopsyNGS

    Residual disease monitoring and prenatal testing

    Sample preparation and stabilization are essential Workflows from sample preparation to bioinformatics

Build on highest-quality sample preparation and stabilization as essential drivers

Sample to Insight    

2016 Analyst & Investor Day    10

Table of Contents

LOGO

 

Case study: Microbiome

~$100 million opportunity

Technology focus areas

Microbiomes first recognized in the 1990s

Challenging samples to extract DNA and RNA

Human microbiome: Bacteria, fungi and viruses

Environmental microbiome: Natural samples

Sample technologies crucial to microbiome research

Extraction from complex    No bias in NGS Turning micro-

metagenomic samples    library preparation biome data

    into insights

Inhibitor removal    

from samples    

QIAGEN microbiome workflows    

    Data

Sample     NGSinter-

processing     library preppretation

MO BIO    Multiplex PCR Plus Microbial

technologies    QIAseq FX DNA Library Genomics

    Pro Suite

To become an essential area in clinical studies and treatment decisions

Sample to Insight

2016 Analyst & Investor Day

11

Table of Contents

LOGO

 

Case study: Single-cell research    Technology focus areas

    20% Immunology

    40% Cancer

    10% Neuroscience

    10% Stem cell

~$150 million    

opportunity    20% Other

    QIAscout – Single-cell isolation for every lab

    Focus on unique cell populations over time

    Analyzing heterogeneous cellular activity PCR

    QIAscoutREPLI-gBioX

    ~100 cells per sample drive insights NGS

    Analyze expression at extreme level of sensitivity

Leverage QIAGEN workflows to support democratization of single-cell research

Sample to Insight    

2016 Analyst & Investor Day    12

Table of Contents

LOGO

 

Single-cell research:    Microbiome:

Practical solutions    Creating the standards

Bioinformatics:     Liquid biopsy:

Further integration into workflows    Sample to Lowering limits of detection

Insight user    

experience    

Sample technologies:     Automation solutions:

Faster, easier, better     Improving lab workflows

In-situ genomics:    Human ID / Forensics:

Moving beyond sequencing    Reliability and accessibility

2017-2020 R&D themes: New solutions to better transform samples into insights

Sample to Insight

2016 Analyst & Investor Day

13

Table of Contents

LOGO

 

A trusted innovator in Life Science Research Unique position to deliver solutions Differentiation with the best user experience Transforming samples into valuable insights

Sample to Insight

2016 Analyst & Investor Day 14

Table of Contents

Exhibit 99.4

LOGO

 

Molecular Diagnostics:

Addressing urgent healthcare issues with innovative solutions

Thierry Bernard

Senior Vice President, Head of Molecular Diagnostics Business Area November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Disclaimer

Table of Contents

LOGO

 

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Sample to Insight *Cleveland Clinic 2017 Medical Innovations

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

Molecular Diagnostics    Waltham, Manchester,

Massachusetts    England

Thierry Bernard    

Senior Vice President,    

Business Area     Hilden,Shenzen,

Molecular Diagnostics     GermanyChina

Joined QIAGEN in 2015    

2015 total sales: $637 million    

Germantown,    Wroclaw,

Molecular Diagnostics employees: ~500    Maryland Poland

Addressable market    Opportunity AdvantagesValue proposition

Deliver strong growth in     Leverage Life Science Offer complete Sample

~15-20%    key focus areas: innovations for clinical useto Insight solutions

share     Oncology Unparalleled leader in Unique ability to serve

    Immune Monitoringsample technologieslabs from LDTs to IVDs

~$3-4 billion     Infectious Diseases Full offerings in targeted Target unmet medical

    patient care continuumsneeds

QIAGEN is addressing urgent healthcare issues with innovative solutions

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

Key trends in molecular diagnostics

MDx: Fastest growth within IVD sector

Untapped potential in emerging markets

Cost pressures and need for clinical value

Demand for breakthroughs

Lab consolidation and decentralization of testing

QIAGEN implications

Focus and differentiation to avoid price wars

Invest in local teams and partners

Showing clinical benefits requires investments

Leverage Life Science innovations to IVD

Need for integrated, easy-to-use scalable systems

Franchise    Focus area QIAGEN market shareTrend

Clinical NGS    ~5%

Oncology    Molecular Personalized Healthcare ~60%

HPV    ~50%

TB management / IGRA test    ~25% / ~85%

Immune Monitoring    

Transplant diagnostics    ~15%

Women’s health    ~15%

Infectious Diseases    

Blood-borne diseases    ~5%

Molecular Diagnostics making an increasingly bigger impact on healthcare

Sample to Insight

2016 Analyst & Investor Day

5

Table of Contents

LOGO

 

Covering the most attractive Molecular Diagnostics segments

QIAGEN’s differentiated offering addressing urgent healthcare needs:

Immune Monitoring

Oncology

Infectious Diseases

Complete Sample to Insight solutions: Scalable workflows using different technologies

Our ambition: A QIAGEN Sample to Insight solution in every MDx lab worldwide

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

Immune Monitoring: Expand QuantiFERON benefits 2020 sales target: >$300 million from QuantiFERON-TB

Oncology: Accelerate lead in Personalized Healthcare Expanding offering from PCR to NGS with GeneReader

Infectious Diseases: Maximize portfolio strengths

QIAsymphony as flagship automation solution

Deliver innovations

Enhance our focused market leadership positions

Strategy: Strengthen our top 3 leadership position with differentiated portfolios

Sample to Insight

2016 Analyst & Investor Day

7

Table of Contents

LOGO

 

Immune Monitoring: Expand QuantiFERON benefits    Total

    convertible skin

    test market:

2020 target: >$300 million sales    ~65 million

    Intensify commercial activities in strategic marketstests annually

    Automation upgrades to improve workflow

North America     Continue menu expansionChina

    Market: ~15 million skin tests Market: ~15 million skin tests

    U.S. submission of QFT-Plus in 2016 (available to QFT)

    Commercial power: Adding reps Build networks and drive

    clinical demand

     Support LTBI guidelines

Latin America     Japan

    Market: ~8 million skin tests Market: ~7 million skin tests

    Support public health 2017: Launch QFT-Plus

guidelines (WHO)     Develop commercial

    partner network

Europe / Middle    Asia-Pacific

East / Africa     Market: ~15 million skin tests

    Market: ~5 million skin tests Highest TB burden region

    Dubai hub to expand Go direct in attractive markets

    regional activities Influence guidelines

QuantiFERON-TB: Drive commercial success through targeted global actions

Sample to Insight

2016 Analyst & Investor Day

8

Table of Contents

LOGO

 

Oncology: Accelerate lead in Personalized Healthcare    

Enabling insights along cancer care continuum     Industry-leading pharma collaborations

Cervical    Lung ColonBreastHematology

    NEW

digene    GeneReader NGS therascreenipsogen

The proven gold standard    First complete Sample to No. 1 portfolio of solid tumorWidest range of molecular

for cervical cancer detection    Insight NGS solution, expansion companion diagnosticstests for blood cancer

to companion diagnostics    

Disease unknown    Disease suspected Disease diagnosedDisease monitoring

Hybrid Capture (HC2)    Next-generation sequencing Targeted PCR / NGSTargeted PCR / NGS

Population screening    Metastatic cancers Resistance detectionRefraction

Initial diagnosis    Treatment modificationRecurrence

Translational research    Companion diagnostics

Providing critical diagnostic solutions across clinical disease progression    

Sample to Insight    

2016 Analyst & Investor Day     9

Table of Contents

LOGO

 

Infectious Diseases: Maximize portfolio strengths    

Broad menu     Broad menu offering

on one     OpenContinuousRandom

system?    channel? loading?access?

    ??

-     ?--

-     ?--

-     -??

-     ?--

Roche: cobas 4800, BD: BD MAX, Hologic:Panther, Abbott: m2000    

QIAsymphony cumulative placements     Flexibility across multiple applications

2,500    

    >2,000

2,000     >1,750

    >1,500

1,500    >1,250

>1,000    

1,000    

500    

0    

2013    2014 201520162017

    targettarget

Highly versatile QIAsymphony as foundation    for Infectious Diseasesexpansion

BBV – Blood-borne virus TPx – Transplantation HAI – Healthcare-acquired infections    WH – Women’s health

Sample to Insight    

2016 Analyst & Investor Day     10

Table of Contents

LOGO

 

Deliver innovations: Enhance our focused market leadership positions    

2017    2018-2020

Menu expansion    System enhancements

    Infectious diseases

GeneReader    Breast cancer NGS system enhancements

    GeneReader v1.1(RUO) (Incl. open channel)Comprehensive

NGS System    Oncohematology and additionalCancer Panel (RUO)

Lung cancer    performance upgrades

Custom channel    NIPT samples (RUO)CE/FDA IVD solutions

Assays    Instrument / Workflow

QFT-TB 4G:    

QuantiFERON    - FDA approval AutomationQuantiFERON Monitor (U.S.)Menu expansion

- Japan approval    improvementsQuantiFERON CMV (U.S.)

New Oncology assays    Infectious DiseaseHPV

CALR CE-IVD    QS-RGQ CMV

ALK CE-IVD    (U.S. submission)

QIAsymphony /    JAK2 PMA QIAsymphony RGQ

    QIAsure methyl marker

PCR    JAK2 Japan Enhanced HCVQIAscreen (CE-IVD)

PITX2    

EGFR new    Limit of Detection

Free circulating DNA    

Preanalytics    (ccfDNA) CE / FDA

IVD claims    

Active pipeline to develop new innovations enhancing our leadership positions

Sample to Insight RUO – Research use only    FDA – U.S. Food and Drug Administration     CE-IVD – CE mark

2016 Analyst & Investor Day 11

Table of Contents

LOGO

 

Unique portfolio of solutions from LDT to IVD tests Focus on significant unmet needs with differentiation Offering complete, scalable solutions across continuum Delivering to labs a one-stop shop for molecular solutions

Sample to Insight

2016 Analyst & Investor Day 12

Table of Contents

Exhibit 99.5

LOGO

 

Bioinformatics:

Partner of choice for insights from complex genomic data

Dr. Laura Furmanski, Ph.D.

Senior Vice President, Head of Bioinformatics Business Area November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Table of Contents

LOGO

 

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Sample to Insight

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

Bioinformatics

Laura Furmanski

Senior Vice President, Business Area Bioinformatics Joined QIAGEN in 2014

2015    total sales: ~$45-50 million Redwood City,

    California

~75%    in Academia, Pharma and Applied Testing

~25%    in Molecular Diagnostics Waltham,

    Massachusetts

Aarhus, Denmark

Bioinformatics employees: ~250     Frederick,Manchester,

    MarylandEngland

Addressable market    Opportunity AdvantagesValue proposition

    Market leader in New technologies Market leader in

    analysis, interpretationvia Life Sciencescontent-driven analytics

~25%     and content Deep customer focus Increasing differentiation

share     Use partners worldwideand market knowledgefor QIAGEN workflows

~$220 million     to extend presence

Recognized for enterprise-grade bioinformatics solutions    

Sample to Insight    

2016 Analyst & Investor Day     4

Table of Contents

LOGO

 

Customers face significant challenges with their genomic data

Hard to extract     Difficulty scaling

insights from     interpretation

increasingly large &     and reporting due to

complex data     skills and turnaround

    time requirements

Lacking skills and    

time to integrate    Customer Cost base is too high,

    particularly with current

products from    challenges reimbursement

different vendors    

Need to keep pace    Slow and difficult to

with fast-moving    expand test menu

science    

Intense pressure to get insights from complex genomic data

Sample to Insight

2016 Analyst & Investor Day

5

Table of Contents

LOGO

 

QIAGEN     QIAGEN

Core capabilities    

Life Sciences portfolio     Clinical portfolio

Microbial Pro Suite     IVA

Microbial RNA-Seq    

    HGMD

Microbial Epigenetics    

Algorithm development    

RNA-Seq Explorer     QCI-Analyze

Services    

IPA     QCI-Interpret

Knowledge base    

Genomics Workbench    curation Biomedical Workbench

Genomics Server    

HVSS     HVSS

Our ambition: Best suite of products for Life Sciences and Molecular Diagnostics

Sample to Insight    

2016 Analyst & Investor Day     6

Table of Contents

LOGO

 

Push the frontiers of science

Delivering cutting-edge bioinformatics solutions

Drive Sample to Insight across QIAGEN Supporting differentiated and complete workflows

Set new standards for clinical support

Advancing the use of genomic data for patients

Efficiently scale the bioinformatics portfolio Raising QIAGEN’s value contribution

Strategy: Increasing focus on Sample to Insight workflows

Sample to Insight

2016 Analyst & Investor Day

7

Table of Contents

LOGO

 

Case study: RNA-seq Explorer uncovers causal genes and variants

Unify and    Reduce Interpret

simplify    time from gene

experiment    expression

tools    to report patterns

Key challenges    Range of applications

    Data overflow hinders Drug target discovery

biological insights     Cancer profiling and

    Integrated tools for clear liquid biopsy

interpretation     Biomarker discovery for

    Bioinformatics expertise clinical development

Built on the foundation of Ingenuity Pathway Analysis (IPA)

Cutting-edge bioinformatics solutions that enable customers to gain insights

Sample to Insight

2016 Analyst & Investor Day

8

Table of Contents

LOGO

 

Case study: Microbial Genomics Pro Suite turns microbiomes into insights

Extraction    Inhibitor AmplificationConverting data

bias    removal biasinto insight

Insight

Sample NGS library Data processing preparation interpretation

Processing massive Comparative analytics: sample data is not enough Key for microbiome research

Best-in-class algorithms for microbiome profiling and comparative analytics

Complete Sample to Insight workflows with integrated microbiome research

Sample to Insight

2016 Analyst & Investor Day 9

Table of Contents

LOGO

 

Case study: QIAGEN Clinical Insight is an integral part of GeneReader NGS workflow

Identify    

QCI workflow     AnalyzeReviewReport

variants    

Full integration for fast and seamless data analysis

Easy-to-use analysis tool for clinical researchers

Efficient pre-designed data analysis optimized to panel content

Operational scale: workflow and decision-assisted automation

Aligned with regulatory and reimbursement requirements

Integration of HGMD (Human Gene Mutation Database)

Setting new standards with QIAGEN Clinical Insight in clinical decision making

Sample to Insight

2016 Analyst & Investor Day

10

Table of Contents

LOGO

 

Case study: the power of QIAGEN Bioinformatics    

Case study: QCI interpretation time benefits    Case study: Cardiology variant classification(1)

90    75%90

    time reduction33% reduction in

80    80variants of unknown

70    70significance

60    60

50    50

Hours    40 Variants40

30    30

20    20

10    10

0    0

Manual    QCI InterpretPathogenic LikelyVUSLikelyBenign

    PathogenicBenign

Literature curation    InterpretationWithout QIAGENWith QIAGEN

Helping to achieve faster and more accurate insights    

Sample to Insight

(1) Data from QCI Interpret with and without QIAGEN curated primary literature.

Data is represented as the difference between variant classifications with QIAGEN content minus variant classifications without QIAGEN content.

2016 Analyst & Investor Day

11

Table of Contents

LOGO

 

“We truly are a Sample to Insight laboratory. As a result, we are bringing greater understanding to a wide range of important medical issues, particularly in cancer.”

Dr. Lars Joensen

Head of NGS Core Unit, Center for Genomic Medicine Rigshospitalet, Copenhagen

“Analysis is a bottleneck and it is not going to get easier in the future. The only solution is to analyze the data quicker and QIAGEN allows us to do this – faster and better.”

Indresh Singh

Senior Bioinformatics Engineer, JCVI

“Assembling allele frequency information in a comprehensive fashion over many different populations is a critical element of genome interpretation, and making it available as a public resource is the right way to do it.”

Dr. Eric Schadt

Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai

40,000 active users across the QIAGEN bioinformatics product offering

Sample to Insight

2016 Analyst & Investor Day

12

Table of Contents

LOGO

 

Market leader in analysis, interpretation and content Portfolio with strong commercial traction Solving challenges of complex genomic data Focusing on delivering Sample to Insight solutions

Sample to Insight

2016 Analyst & Investor Day 13

Table of Contents

Exhibit 99.6

LOGO

 

Commercial Operations:

Engaging customers with our Sample to Insight portfolio

Manuel O. Méndez

Senior Vice President, Head of Global Commercial Operations November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Disclaimer

Table of Contents

LOGO

 

Safe are, or Harbor may be Statement: deemed toThis be forward presentation looking contains statements both within historical theand meaning forward of-Section looking statements 27A of the .UAll .S.statements Securities Act other ofthan 1933, statements as amended, of historical and Section fact 21E assumptions of the U.prove S. Securities inaccurate Exchange or unknown Act of risks 1934,or asuncertainties amended. These materialize, statements actual are results basedcould on current vary materially expectations from of future our own events expectations . If underlying and competition; projections. Some risks associated of the factors withthat managing could cause growthactual and international results to differ operations include, (including but are the not effects limited,of tocurrency the following: fluctuations, general regulatory industry conditions processes and and products dependence to customers on logistics), in academia, variability of pharma, operating applied results testing and allocations and molecular between diagnostics; customer changing classes,relationships and the commercial with customers, development suppliers of markets and strategic for our partners; economiccompetition; conditions, the rapid level or unexpected and timing of changes customers’ in technologies; funding, budgets fluctuations and other in demand factors);for our QIAGEN’s ability to products obtain regulatory (including approval factors such of ouras products; general technological producing such advances products; of our the competitors ability of QIAGEN and related to identify legal disputes; and develop difficulties new products in successfully and toadapting differentiate QIAGEN’s and protect products ourto products integrated from solutions competitor and to products; “Risk Factors” market acceptance section of reports of QIAGEN’s that QIAGEN new products has filed and with, theor integration furnishedof to, acquired the U.Stechnologies . Securities and andExchange businesses Commission . For further(SEC) information, . We undertake please refer no extent obligation, required and do by not law.intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the accepted Regulation accounting G: QIAGEN principles), reports adjusted to provide results, additional as well insight as results on performance on a constant . In this exchange presentation, rate (CER) adjusted basis,results and other include non-adjusted U.S. GAAP operating figuresexpenses, (generally adjusted addition to EBITDA, reported adjusted results diluted prepared EPS in and accordance free cash with flow GAAP, . Adjusted but should results not are be non considered -GAAP financial as a substitute measures . QIAGEN QIAGEN believes believes should certainbe items considered should be in results excluded with from itsadjusted competitors results and when its own theyprior are outside periodsof . Please its ongoing see core the Appendix operations, provided vary significantly in this presentation from period“Reconciliation to period, or affect of Non the-GAAP comparability to GAAP of QIAGEN Measures” does for not reconciliations reconcile forward of historical -lookingnon non -GAAP -GAAPmeasures financial measures to comparable to the GAAP corresponding measures GAAP andmeasures the definitions due to ofthe terms highused variability in the and presentation difficulty in. making GAAP financial accuratemeasures forecasts to and the projections corresponding that are GAAP impacted measures by future are not decisions available and without actions unreasonable . Accordingly,effort reconciliations . However,of the these actual forward amounts -looking of these non-excluded items will have a significant impact on QIAGEN’s GAAP results.

QIAGEN GeneReader GeneReader® NGS System: NGS The System QIAGEN with new GeneReader® sequencing chemistry NGS System will be is made currently available available in the forUnited marketing States and starting salesinoutside December the 2016 United . The States QIAGEN . The GeneReader® QIAGEN Clinical NGS Insight® System is is anintended evidence for -based Research decision Usesupport Only. This software product intended is not intended as an aid forinthe thediagnosis, interpretation prevention of variants or treatment observed ofin a genomic disease. available sequencing databases data. The and software annotations, evaluates drug genomic labels and variants clinical in -the trials context . Based ofon published this evaluation, biomedical theliterature, software professional proposes a association classification guidelines, and bibliographic publicly references substitute for to aid professional in the interpretation healthcare of advice observed . Each variants laboratory . Theissoftware responsible is not for intended ensuring ascompliance a primary diagnostic with applicable tool by international, physicians or national to be used and local as a clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Sample to Insight

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

Commercial Operations    Waltham, Manchester,

Massachusetts    England

Manuel O. Méndez    

Senior Vice President,    

Global Commercial Operations     Hilden,Shenzen,

    GermanyChina

Joined QIAGEN in 2014    

2015 total sales: ~$1.3 billion    

Germantown,    Wroclaw,

Commercial Operations employees: ~1,800    Maryland Poland

Opportunity    Value proposition

    Addressing needs of >500,000 Powerful brand

customers worldwide     Differentiated portfolio

    Ability to serve Life Science and Focus on Sample to Insight solutions

Molecular Diagnostics markets     Critical mass in attractive markets

QIAGEN benefitting from increasing prevalence and pace of molecular testing

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

Clinical trends drive growth

Cost of ownership

Multiple decision makers

MDx

Fragmented market

Customer funding / breakthroughs Technically savvy sales teams Large aggregators and Life smaller players Sciences Centralized or decentralized purchasing

QIAGEN implications

Strengthen role as top 3 global competitor

Leverage access to ~80% of $5-6 bn MDx market

Target growth in areas with differentiated profile:

Oncology

Immune Monitoring

Infectious Diseases

QIAGEN implications

Capitalize on strong brand and customer base

Focus on differentiated workflows

Deploy specialist teams to support generalists

Serve customers through preferred channels

QIAGEN positioned for success due to agility, S2I workflows and strong brand

Sample to Insight

2016 Analyst & Investor Day

5

Table of Contents

LOGO

 

Drive commercial teams with efficiency and effectiveness Experienced leaders using data-driven tools

Invest in geographic expansion

Capitalizing on established and emerging markets

Optimize customer engagement

Omni-channel approach using multiple channels

Create value with our Sample to Insight portfolio Agile and focused teams delivering solid sales growth

Strategy: Deliver solid sales growth efficiently as leader in enabling insights

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

NEW TO QIAGEN    

Manuel O. Méndez    Mohammad El Khoury

President (Interim)    President

Commercial Operations    Commercial Operations

North America    Europe / Middle East / Africa

Formerly bioMerieux, Abbott, Thermo    Formerly GE, bioMerieux

NEW TO QIAGEN    NEW ROLE

Enrique Razzeto    Ian Martin

Vice President    President

Commercial Operations    Commercial Operations

Latin America    Asia-Pacific

Formerly Abbott, Dako    Formerly Abbott

NEW TO QIAGEN    NEW ROLE NEW ROLE

Scott MacPherson    Wolfgang Leibinger, Ph.D. Hans Peter Fatscher, Ph.D.

Vice President    Vice President Vice President

Global Key & Corporate Accounts    Global Marketing ComOps Custom by QIAGEN

Formerly Abbott, Bayer    Formerly Millipore Formerly Boehringer Ingelheim

NEW TO QIAGEN    NEW TO QIAGEN

Kesava Nagar-Anthal, Ph.D.    Vera M. Bökenbrink

Vice President    Senior Director ComOps Finance

Commercial Excellence    and Business Analytics

& Effectiveness    Formerly Kirchhoff Automotive, FEV Motorentechnik

Formerly bioMerieux, BD, Thermo    

Manuel O. Méndez    In last 12-18 months

Senior Vice President    NEW TO QIAGEN

Global Commercial Operations    

Formerly bioMerieux, Abbott, Thermo    NEW ROLE

Significant executive leadership changes implemented while growing sales

Sample to Insight    

2016 Analyst & Investor Day     7

Table of Contents

LOGO

 

Results and accountability driven-culture    

    New “go-to-market” strategy QIAGEN sales trends (CER % change)

    9%

    7%5% 5%5%6%

    Leading and lagging indicators 3% 3%4% 4%4% 2%3% 2%

    2%

    Pipeline management

    Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3

    Demand generation2013 2013 2013 2013 2014 2014 20142014 2015 2015 20152015 2016 2016 2016

    QIAGEN sales per S&M FTE ratio (In $ thousands)

    Promote and pay for performance ~690~710~640~630

    Investment in training and tools

    CRM systems (Salesforce.com)

    2013201420152016 Target

    QIAGEN S&M OPEX ratio (% of sales)

    Focus on productivity metrics

    Sales by S&M FTE ratio28.4%28.0%28.2%27.9%

    S&M OPEX to sales ratio

    Number of calls per day (36% increase)

    2013201420152016 Target

    Fully focused on sales growth to drive efficiency and effectiveness

Sample to Insight

2016 Analyst & Investor Day

8

Table of Contents

LOGO

 

Geographic expansion

Emerging markets

Expanding commercial partner network

Case study: >20% CER in 2016

Direct QIAGEN presence

Dubai, Thailand

Case study: South Africa >50% CER in 2016

Established markets

North America investments in QuantiFERON

Case study: >28% CER growth in 2016

Flexible investment with third-party sales forces

Global key accounts

Senior-level engagement with top accounts

Case study: >26% CER growth in 2016

Targeted investments to drive growth in established and emerging markets

Sample to Insight

2016 Analyst & Investor Day

9

Table of Contents

LOGO

 

Academia    Pharma Applied TestingMolecular Diagnostics

Scientific breakthroughs    Better and safer drugs Secure and protectBetter healthcare

    Generalists and Specialists

Direct mail     Mobile content

Marketing    

automation     Websites

Inside Sales    eCommerce

Customer Care    

Field Service Support    

Case studies     Sales enablement tools

Commercial Partners    

Omni-channel customer engagement creates value with digital accessibility

Sample to Insight

2016 Analyst & Investor Day

10

Table of Contents

LOGO

 

Academia    Pharma Applied TestingMolecular Diagnostics

Scientific breakthroughs    Better and safer drugs Secure and protectBetter healthcare

Case study: New York

Memorial Sloan Kettering    Pfizer Pharmaceuticals

New York University (NYU)    NYC Chief Medical Examiner

Leverage Sample to Insight portfolio for customer types and preferred channels

Sample to Insight    

2016 Analyst & Investor Day    11

Table of Contents

LOGO

 

Case study: Leveraging benefits of NGS Sample to Insight workflows    

    Platform

    agnostic

Nucleic acid    TargetLibraryData

collection &    enrichmentpreparationanalysisInterpretation

extraction    

    GeneReader

    NGS

    System

Automation    

QIAcube    QIAgilityQIAcubeGeneReadGene-QCI-QCI-

    QIAcubeReaderAnalyzeInterpret

QIAamp    QIAseqQIAseq FXQIAseqMicrobial

Solutions    Circulating NA Targeted RNADNA LibraryQIAactGenomics Pro Suite

Applications    Liquid biopsy Single-cell researchMicrobiome

Sample to Insight workflows creating value for many customers    

Sample to Insight    

2016 Analyst & Investor Day     12

Table of Contents

LOGO

 

Experienced commercial team using data-driven tools

Targeted geographic investments to accelerate growth

Optimizing customer engagement in multiple channels

Agile and focused teams with improved sales efficiency

Sample to Insight

2016 Analyst & Investor Day

13

Table of Contents

Exhibit 99.7

LOGO

 

Multiple drivers to improve returns and create greater value

Roland Sackers Chief Financial Officer November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Table of Contents

LOGO

 

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Sample to Insight

2016 Analyst & Investor Day 3

Table of Contents

LOGO

 

2013-2016: Net sales growth trends

(At constant exchange rates to comparative year)

10%

8%

6%

4%

2%

0%

2013

2014

2015

9M

2016

2016

guidance

Total CER sales growth excluding U.S. HPV sales Total CER sales growth

2013-2016: Key challenges

U.S. HPV decline worse than expected – impact on sales and profitability

Restricted Life Sciences funding

Significant FX headwinds

2013-2016: Major actions

Portfolio transformation and investments

GeneReader NGS System launch

Built up infrastructure and global operating platform – future scalability and leverage

Regional expansion and organizational changes

Efficiency initiatives to support growth

2016: QIAGEN at an inflection point for new growth and value creation trajectory

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

2020: Net sales growth target

(At constant exchange rates to comparative year)

~+7-9% CER

CAGR

2020: Adjusted diluted EPS target

(In $ per share, at CER to comparative year)

>12% CER

CAGR

+6-7% CER    ~$1.08-1.09

$ 1,281 m     (~1.10-1.11 CER)

+3% CER     $1.05

~$0.87-0.88 CER

with restructuring

2015    2016 2016-2020201520162016-2020

guidance    targetguidancetarget

2020 targets: Strong focus on sales growth and operational execution

Sample to Insight

2016 Analyst & Investor Day

5

Table of Contents

LOGO

 

Invest in growth opportunities

Allocate more resources to most attractive areas

Generate operating leverage

Optimize cost base while sustaining sales growth

Step up operating cash flow

Achieve ~$600 million target for 2020

Ensure disciplined capital deployment Invest in QIAGEN while increasing returns

Strategy: Multiple drivers to improve returns and create greater value

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

Growth drivers

EGM expansion

Digitalization

QuantiFERON-TB

GeneReader NGS System and universal NGS solutions

QIAsymphony

Personalized Healthcare

Differentiated Technologies

Middle East (Dubai and Egypt)

Africa (South Africa)

Asia (Thailand)

Exploit new business models

Digitalization of operating model

Big data and analytics

Social media engagement

Cyber security

Case study: Resource allocation    Case study: South Korea “QIAGEN works Digital” roadmap

    Expand QuantiFERON-TB sales >20% CER growth (2013-16 CAGR)New Digital Accelerator team

activities in key markets (U.S., EU)    with ~50 employees

Investing in top portfolio areas, most attractive regions and digital initiatives

Sample to Insight

2016 Analyst & Investor Day

7

Table of Contents

LOGO

 

Key efficiency initiatives    Adjusted operating expenses(1)

    (As % of net sales)

1    

Sales channel    Increase sales per FTE ratio 47%48%47%49%~46-47% CER~44-45%

optimization    and sales over OPEX ratio CER

2    

Site    Focus on key sites and

consolidation    reduce legal entities

3    

Business Service    Leverage shared service

Centers    hubs in Poland and China

4    

Portfolio    Divest smaller non-core

management    portfolio areas

    2013201420159M 201620162017

    guidancetarget

Stronger “continuous improvement” mindset    to deliver operationalleverage

Sample to Insight (1) 2016 and 2017 figures are estimates before restructuring charges and at constant exchange rates (CER) for comparative year

2016 Analyst & Investor Day 8

Table of Contents

LOGO

 

Manufacturing productivity gains     Development cost structure

Product cost index (As % of 2013 costs)     MDX development employees (As % of total)

Hilden    GermantownEmployees at other sites

    ~40%

100    90 ~80-8510095~85-90~75%~60%Employees in

    Centers of Excellence

    ~40%~60%

    ~25%

2013    2016 2020 target201320162020 target201320162020

    target

Insourcing initiatives and network consolidation

QIAzen    

Supply chain management optimization    

Sales & Marketing efficiency    

Net sales per S&M FTE    Net sales share in digital channels

(In $ thousands)     (In % of total sales)

~$690     ~$720 CER~50%

~$630    ~30%

    ~25%

2013    2016 2020 target201320162020 target

Invest in Centers of Excellence for product development:

>~200 employees in Manchester targeted for 2017

Building new integrated software development group

Improve simplicity and agility, realize economies of scale

Business Service Center functions

Leverage investments in teams and digital infrastructure

Efficiently manage cost per touchpoint across channel mix

Improve Marketing efficiency and effectiveness with alignment and new Centers of Excellence

Sample to Insight

2016 Analyst & Investor Day

2013    20162020 target

BSC employees:    ~50 ~200> ~400

Major functions and shared service potential:    

Finance    

Procurement    

Human Resources    

Customer Care    

SCM/ Logistics    

    9

Table of Contents

LOGO

 

Cash flow considerations    2020: Operating cash flow target(1)

(In $ millions)    

1     ~$600 m

Working capital    

management    

2     ~$350 m

Benefits of     $318 m

    $288 m

efficiency gains    $259 m

3    

Maintain DSOs with    

geographic expansion    

4    

Disciplined capex    

investments    2013 2014201520162020

    guidancetarget

Setting a 2020 target to reach    ~$600 million of operating cashflow

Sample to Insight (1) 2016 and 2020 targets before restructuring charges and based on current exchange rates.

2016 Analyst & Investor Day 10

Table of Contents

LOGO

 

2012-2017: QIAGEN capital returns

(In $ millions)

~$514 m

    $387 m~$300 m

    ~$272 m

    ~$50 m

    $251 m

~$    86 m~$250 m

~$36 m     $127 m

    $21 m

2012    2013 201420152017

Open market share repurchase    

Planned synthetic share repurchase    

Convertible notes repurchases(1)    

Planned open market repurchase in 2017    

Return considerations

2017: Commitment to return $300 million

~$250 million via synthetic share repurchase (completion in January)

~$50 million via open-market repurchases (completion by end of 2017)

Mid-term targets do not assume repurchases beyond announced 2017 programs

Signal of conviction with $300 million capital return commitment by end of 2017

(1) 2026 convertible notes repurchased in 2014 removed ~2 million shares from diluted share count and ~15 million total shares of dilution risk (dilutive above $20.00) 2024 convertible notes repurchased in 2015 removed ~5 million shares from diluted shared count and ~12 million total shares of dilution risk (dilutive above $12.65)

Sample to Insight

2016 Analyst & Investor Day

11

Table of Contents

LOGO

 

2013-2017: Leverage ratio(1)    

(Multiple of net debt / EBITDA)    

2.0    

1.6    

1.5    

1.5    

1.3     ~1.3

1.1    

1.0    

0.5    

0.0    

2013    2014 20159M2017

    2016year-end

    target

2017-2024:    Debt maturity overview

(In $ millions)    

2024    $27 m U.S. Private Placement

    (3.9%)

2023    

2022     $300 mU.S. Private Placement

    (3.75%)

2021     $300 mCash convertible notes

    (0.875%)

2020    

    Cash convertible notes

    $430 m(0.375%)

2019    

    U.S. Private Placement

$75 m    (3.19%)

2018    

2017    

Healthy leverage and capital structure to support business and increase returns

(1) Leverage ratio is calculated on trailing four quarters as net debt / EBITDA adjusted for acquisition-related expenses, share-based compensation and pro forma results of acquired businesses. 2017 estimate without future M&A.

Sample to Insight

2016 Analyst & Investor Day

12

Table of Contents

LOGO

 

2017: Net sales guidance     2017: Adjusted diluted EPS guidance

(At constant exchange rates to comparative year)    (In $ per share, at CER to comparative year)

    ~$0.13-~$1.25-

Exiqon    ~+6-7% CER ~+6-7% CER0.16 CER~$0.03 CER1.27 CER

acquisition     ~1.08-1.09

(June 2016)     ~1 p.p.Exiqon(~$1.10-1.11 CER)

MO BIO    ~2 p.p.

acquisition    

(late 2015)    

    ~$1.22-1.24 CER

    ~$0.87-0.88 CERwith restructuring

    Rest of

    ~5-6 p.p.business(1)with restructuring

Rest of    

business(1)    ~4-5 p.p.

2016    2017 2016Operating~$300 m2017

guidance    guidance guidanceperformanceshareguidance

    repurchase

2017 guidance: Goals for strong sales growth and adjusted    EPS expansion

(1) Includes U.S. HPV headwinds of estimated ~1 p.p. for both 2016 and 2017    

p.p. – Percentage points CER – Constant exchange rates    Exiqon sales consolidated as of July 1, 2016

Sample to Insight    

2016 Analyst & Investor Day     13

Table of Contents

LOGO

 

2016-2020: Adjusted diluted EPS growth target    

(In $ per share, at CER to comparative year)    

    OperationalNon-operational

Organic    GrossOperatingTaxShare

sales growth    marginexpense ratioratecount

    >12% CER

    CAGR

+    Strong portfolio + Capacity+Sales channel-Higher profits+ 2017 share

expansion    utilizationoptimization-OECD taxrepurchases

+    Reduced + Automation+Fewer sitesdiscussionsTargets do not

~$1.08-1.09    U.S. HPV - Product mix+Business centersassume returns

(~$1.10-1.11 CER)    headwinds beyond 2017

    +Portfolio

    management

    -Bioinformatics

    (OPEX per sales)

2016     2016-2020

guidance     target

before    

restructuring    

Targeting leverage opportunities to generate double-digit adjusted EPS growth

CER – Constant exchange rates    

Sample to Insight    

2016 Analyst & Investor Day     14

Table of Contents

LOGO

 

Key assumptions: 2016-2020

(As of November 15, 2016)

Capital expenditure (PP&E)

Capital expenditure (Intangibles) (Excluding acquired IP) Depreciation and amortization (Excluding acquired IP)

Amortization of acquired IP (Excluding any future M&A)

Restructuring charges (Included in adjusted results) Net interest expense (Included in adjusted results)

Adjusted tax rate

Repurchase considerations Weighted average diluted number of shares(1) FX assumptions

2016    2017 2018-2020

~5% of sales    ~5% of sales ~4-5% of sales

~1-2% of sales    ~2-3% of sales ~2-3% of sales

~7% of sales    ~7% of sales ~6-7% of sales

    2018: ~$90 million

~$120 million    ~$105-110 million 2019: ~$70 million

    2020: ~$50 million

~$75 million    ~$10 million

~$12-14 million    ~$13-15 million ~$15-20 million

~12-13% / ~16-17%    ~18% ~19-20%

(With / without restructuring charge)    

–    ~$300 m Under consideration

~238 million    ~232 million Depending on

(Includes $300 m repurchase)    capital returns

Net sales: ~-1-2 ppts    Net sales: ~-1 ppt

Adjusted EPS: ~-$0.01-0.02    Adjusted EPS: ~-$0.01-0.02

(1) 2017 includes planned $300 m share repurchase. Every $1.00 change in market price per share of common stock above $30.00 share price results in an increase / decrease of ~700,000 in dilutive shares due to call-spread overlay (CSO) related to convertible notes.

Sample to Insight

2016 Analyst & Investor Day

15

Table of Contents

LOGO

 

Multiple drivers to improve returns and create greater value

Sustain strong growth through targeted investments

Sharpen focus on operational and financial leverage

Maintain disciplined capital allocation strategy

Sample to Insight

16

Table of Contents

LOGO

 

Appendix

Sample to Insight

17

Table of Contents

LOGO

 

Q3 2016: Consolidated Statements of Income (unaudited)

Three months ended    Three months ended

(In $ thousands, except share data)    September 30, 2016 September 30, 2015

Net sales    338,685 314,561

Cost of sales    117,879 109,915

Gross profit    220,806 204,646

Adjusted gross profit    241,429 222,300

Operating expenses:    

Research and development    36,202 35,568

Sales and marketing    94,442 88,759

General and administrative, integration and other    33,339 24,562

Acquisition-related intangible amortization    9,851 9,586

Total operating expenses    173,834 158,475

Income from operations    46,972 46,171

Adjusted income from operations    86,763 78,333

Other income (expense):    

Interest income    1,658 1,283

Interest expense    (9,626) (9,206)

Other expense, net    (2,374) (684)

Total other expense, net    (10,342) (8,607)

Income before income taxes    36,630 37,564

Adjusted income before income taxes    82,197 75,121

Income taxes    2,922 3,550

Adjusted income tax    14,014 11,868

Net income    33,708 34,014

Net (loss) income attributable to non-controlling interest     (53)84

Net income attributable to the owners of QIAGEN N.V.    33,761 33,930

Adjusted net income attributable to the owners of QIAGEN N.V.    68,236 63,169

Diluted net income per common share attributable to the owners of QIAGEN N.V.    $0.14$0.14

Adjusted diluted net income per common share attributable to the owners of QIAGEN N.V.    $0.29$0.27

Diluted shares used in computing diluted net income per common share (in thousands)    238,343 237,105

Sample to Insight    

Third quarter and first nine months 2016 results     18

Table of Contents

LOGO

 

First nine months 2016: Consolidated Statements of Income (unaudited)

Nine months ended    Nine months ended

(In $ thousands, except share data)    September 30, 2016 September 30, 2015

Net sales    971,476 932,446

Cost of sales    355,025 329,388

Gross profit    616,451 603,058

Adjusted gross profit    683,248 666,076

Operating expenses:    

Research and development    118,082 107,471

Sales and marketing    287,185 267,200

General and administrative, integration and other    89,943 78,210

Acquisition-related intangible amortization    29,387 28,888

Total operating expenses    524,597 481,769

Income from operations    91,854 121,289

Adjusted income from operations    209,297 224,594

Other income (expense):    

Interest income    4,676 3,028

Interest expense    (28,370) (27,746)

Other expense, net     (41)(10,585)

Total other expense, net    (23,735) (35,303)

Income before income taxes    68,119 85,986

Adjusted income before income taxes    201,937 213,970

Income taxes    (1,426) 7,502

Adjusted income tax    32,863 38,402

Net income    69,545 78,484

Net loss attributable to non-controlling interest    (101) (46)

Net income attributable to the owners of QIAGEN N.V.    69,646 78,530

Adjusted net income attributable to the owners of QIAGEN N.V.    169,175 175,614

Diluted net income per common share attributable to the owners of QIAGEN N.V.    $0.29$0.33

Adjusted diluted net income per common share attributable to the owners of QIAGEN N.V.    $0.71$0.74

Diluted shares used in computing diluted net income per common share (in thousands)    237,453 237,172

Sample to Insight    

Third quarter and first nine months 2016 results     19

Table of Contents

LOGO

 

Q3 2016 and 9M 2016: Reconciliation adjusted results    

Net    GrossOperatingPretaxIncomeTaxNetDiluted

(In $ millions, except EPS)    sales profitincomeincometaxrateincomeEPS(1)

Third quarter 2016    

Reported results    338.7 220.847.036.6-2.98%33.80.14

Adjustments    

Business integration and acquisition-related items     0.49.79.7-2.86.90.03

Purchased intangibles amortization     20.230.130.1-10.120.00.09

Non-cash interest expense charges     5.05.00.02

Other special income and expense     0.81.82.50.01

Total adjustments     20.639.845.6-11.134.40.15

Adjusted results    338.7 241.486.882.2-14.017%68.20.29

First nine months 2016    

Reported results    971.5 616.591.968.11.4NM69.60.29

Adjustments    

Business integration and acquisition-related items     6.728.028.0-8.119.90.09

Purchased intangibles amortization     60.089.489.4-30.059.40.25

Non-cash interest expense charges     14.814.80.06

Other special income and expense     1.63.95.50.02

Total adjustments     66.7117.4133.8-34.299.60.42

Adjusted results    971.5 683.2209.3201.9-32.916%169.20.71

(1) Weighted number of diluted shares (Q3 2016: 238.3 million) (9M 2016: 237.5 million)    NM – Not meaningful

Table may have rounding differences. Net income and diluted EPS based on net income attributable to owners of QIAGEN N.V.    

Sample to Insight    

Third quarter and first nine months 2016 results    20

Table of Contents

LOGO

 

Q3 and 9M 2016: Currency impact    

Net sales    Net salesCurrency exposureChange

(In $ m)    (CER)(As % of CER sales)(In $ m)

Third quarter 2016    

U.S. dollar    143.6 143.642%0.0

Euro    72.0 71.821%0.2

British pound    25.7 30.29%-4.5

Japanese yen    12.6 10.63%2.0

Other currencies    84.8 85.625%-0.8

Total net sales    338.7 341.8100%-3.1

First nine months 2016    

U.S. dollar    409.9 409.942%0.0

Euro    217.5 216.922%0.6

British pound    69.8 77.38%-7.5

Japanese yen    37.1 33.43%3.7

Other currencies    237.2 248.025%-10.8

Total net sales    971.5 985.5100%-14.0

Sample to Insight

CER—Constant exchange rates

Other currencies include CAD, DKK, TRY, SEK, CHF, AUD, BRL, CNY, MYR, SGD, KRW, HKD, MXN, INR, TWD, RUB and ZAR

Third quarter and first nine months 2016 results

21

Table of Contents

LOGO

 

2016: Quarterly and YTD income statement summary    

(In $ millions, unless indicated)    

(Diluted EPS in $ per share)    Q1 2016 Q2 2016Q3 2016Q4 2016YTD 2016

Net sales    298.4 334.4338.7971.5

Net sales (CER)    305.6 338.1341.8985.5

Gross profit    184.7 210.9220.8616.5

Gross profit margin    62% 63%65%63%

Adjusted gross profit    207.5 234.4241.4683.2

Adjusted gross profit margin    70% 70%71%70%

Operating income    15.4 29.547.091.9

Operating margin    5% 9%14%9%

Adjusted operating income    53.4 69.286.8209.3

Adjusted operating margin    18% 21%26%22%

Tax rate    -66% 7%8%-2%

Adjusted tax rate    15% 16%17%16%

Net income    14.9 21.033.869.6

Adjusted net income    44.0 56.968.2169.2

Diluted EPS    0.06 0.090.140.29

Adjusted diluted EPS (CER) ($ per share)    0.19 (0.19) 0.24 (0.24)0.29 (0.29)0.71 (0.73)

Diluted shares outstanding for EPS calculation    236.9 237.2238.3237.5

Sample to Insight

CER—Constant exchange rates Table may have rounding differences.

Net income, adjusted net income, diluted EPS and adjusted diluted EPS based on net income attributable to owners of QIAGEN N.V.

Third quarter and first nine months 2016 results

22

Table of Contents

LOGO

 

2015: Quarterly and YTD income statement summary    

(In $ millions, unless indicated)    

(Diluted EPS in $ per share)    Q1 2015 Q2 2015Q3 2015Q4 20159M 2015FY 2015

Net sales    298.4 319.5314.6348.5932.41,281.0

Adjusted net sales    298.7 319.5314.6348.5932.71,281.2

Adjusted net sales (CER)    324.8 348.9342.5372.61,016.21,388.8

Gross profit    197.9 200.5204.6223.3603.1826.4

Gross profit margin    66% 63%65%64%65%65%

Adjusted gross profit    218.1 225.7222.3246.0666.1912.0

Adjusted gross profit margin    73% 71%71%71%71%71%

Operating income    35.1 40.046.254.4121.3175.7

Operating margin    12% 13%15%16%13%14%

Adjusted operating income    67.4 78.978.390.0224.6314.5

Adjusted operating margin    23% 25%25%26%24%25%

Tax rate    -2% 15%10%-4%9%4%

Adjusted tax rate    19% 19%16%15%18%17%

Net income    19.5 25.133.948.678.5127.1

Adjusted net income    51.5 60.963.273.9175.6249.5

Diluted EPS    0.08 0.110.140.200.330.54

Adjusted diluted EPS (CER) ($ per share)    0.22 (0.24) 0.26 (0.28)0.27 (0.29)0.31 (0.33)0.74 (0.81)1.05 (1.13)

Diluted shares outstanding for EPS calculation    237.4 237.0237.1237.1237.2237.2

Sample to Insight

CER—Constant exchange rates Table may have rounding differences

Net income, adjusted net income, diluted EPS and adjusted diluted EPS based on net income attributable to owners of QIAGEN N.V.

Third quarter and first nine months 2016 results

23

Table of Contents

LOGO

 

Consolidated Balance Sheets    

Sept 30,    Dec 31,Sept 30,Dec 31,

(In $ thousands, except par value)    2016 2015(In $ thousands, except par value)20162015

Assets    (unaudited) Liabilities and Equity(unaudited)

Current assets:     Current liabilities:

Cash and cash equivalents    354,646 290,011Accounts payable40,87452,306

Short-term investments    109,693 130,817Accrued and other current liabilities196,963192,069

Accounts receivable, net    260,039 273,853Income taxes payable12,28421,515

Income taxes receivable    26,443 26,940Deferred income taxes—2,463

    Total current liabilities250,121268,353

Inventories, net    144,710 136,586Long-term liabilities:

Prepaid expenses and other current    67,529 70,121

assets     Long-term debt1,069,4401,049,026

Deferred income taxes    — 33,068Deferred income taxes40,35775,726

Total current assets    963,060 961,396Other long-term liabilities302,526224,058

Long-term assets:     Total long-term liabilities1,412,3231,348,810

Property, plant and equipment, net    460,509 442,944Equity:

Goodwill    1,962,514 1,875,698Common shares, EUR 0.01 par value:2,8122,812

Intangible assets, net    623,272 636,421Additional paid-in capital1,764,6531,741,167

Deferred income taxes    7,671 2,036Retained earnings1,273,6051,227,509

    Accumulated other comprehensive

Other long-term assets    311,118 260,622loss(249,070)(259,156)

Total long-term assets    3,365,084 3,217,721Less treasury shares at cost(126,300)(152,412)

Total assets    4,328,144 4,179,117Total equity attributable to the

    owners of QIAGEN N.V.2,665,7002,559,920

    Non-controlling interest—2,034

    Total equity2,665,7002,561,954

    Total liabilities and equity4,328,1444,179,117

Sample to Insight

Third quarter and first nine months 2016 results

24

Table of Contents

LOGO

 

Consolidated Statements of Cash Flows (unaudited)    

Nine months ended    Nine months ended

Sept 30,    Sept 30,Sept 30,Sept 30,

(In $ thousands)    2016 2015(In $ thousands)20162015

Cash flows from operating activities:     Cash flows from financing activities:

Net income    69,545 78,484Net proceeds from issuance of cash

Adjustments to reconcile net income to net     convertible notes and cash paid for

cash provided by operating activities, net of     issuance costs—(86)

effects of businesses acquired:     Repayment of long-term debt(6,738)(251,398)

Depreciation and amortization    156,695 139,666Principal payments on capital leases(949)(809)

Non-cash impairments    — 2,189Proceeds from subscription receivables—97

Deferred income taxes    (11,695) (7,899)

    Excess tax benefits from share-based

Other items, net including fair value     compensation4482,513

changes in derivatives    35,355 50,790

Change in operating assets    17,911 19,560Proceeds from issuance of common shares2,5629,117

Change in operating liabilities    (26,232) (52,055)Purchase of treasury shares—(20,818)

Net cash provided by operating activities    241,579 230,735Other financing activities(11,156)(836)

    Net cash used in financing activities(15,833)(262,220)

Cash flows from investing activities:    

    Effect of exchange rate changes on cash and

Purchases of property, plant and equipment    (54,846) (67,683)cash equivalents2,143(13,088)

Proceeds from sale of equipment    22 103

    Net increase (decrease) in cash and cash

Purchases of intangible assets    (12,694) (14,432)equivalents64,635(61,716)

Purchases of investments    (21,375) (5,596)Cash and cash equivalents, beginning of

Cash paid for acquisitions, net of cash     period290,011392,667

acquired    (90,490) (7,097)Cash and cash equivalents, end of period354,646330,951

Purchases of short-term investments    (436,249) (190,508)

Proceeds from sales of short-term     Reconciliation of Free Cash Flow1

investments    458,883 274,125Net cash provided by operating activities241,579230,735

Other investing activities    (6,505) (6,055)Purchases of property, plant and equipment(54,846)(67,683)

Net cash used in investing activities    (163,254) (17,143)Free Cash Flow186,733163,052

(1) Free cash flow is a non-GAAP financial measure and is calculated from cash provided by operations reduced by the investments in fixed assets. QIAGEN believes this is a common financial measure useful to further evaluate the results of operations.

Sample to Insight

Third quarter and first nine months 2016 results

25

Table of Contents

Exhibit 99.8

LOGO

 

QuantiFERON-TB:

Changing the way the world looks at TB prevention and elimination

Dr. L. Masae Kawamura, M.D.

Senior Director, Medical & Scientific Affairs, TB Diagnostics November 15, 2016

Sample to Insight

2016 Analyst & Investor Day 1

Table of Contents

LOGO

 

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

Tuberculosis: A stealth foe and global killer

CAVITY –Millions to billions of bacilli

Etiology Transmission Impact Global Incidence

Non-motile slow growing bacteria

May persist in the body for decades

Airborne disease

Spread mainly through cough

A person dies of TB every 18 seconds

More deaths from TB than HIV or malaria

10.4 million active TB cases in 2015

2-3 billion latent TB infections globally

TB is preventable, but persists due to ignorance, apathy and poor detection

Sample to Insight

2016 Analyst & Investor Day

3

Table of Contents

LOGO

 

The world is waking up to the importance of latent TB infection and prevention

2,000

1,770 1,600

Active TB case detection and treatment million 1,200 per ases 800

C Mass LTBI detection 400 and treatment Active and latent TB

0 detection and treatment 2010 2020 2030 2040 2050 2015

Multiple studies show addressing latent TB essential to eliminating the disease

LTBI – Latent TB infection

Sample to Insight

Adapted from Abu-Raddad et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. PNAS. 2009; 106; 13980-5.

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

Latent TB market endorsement

2015: UN approves global goal to reduce TB incidence by 80% by 2030

2014: WHO End TB Strategy: Prevention is an essential component

2014: WHO issues guidelines on management of latent TB infection

Scaling up the fight against latent TB

International guidelines expanding latent TB testing beyond developed countries

Targeting 115 countries with TB rates of <100 cases per 100,000

Diagnostic aids: IGRA or TST (skin test)

Eliminating TB requires scaling up the fight on a global basis

Sample to Insight IGRA – Interferon-gamma release assay     TST – Tuberculin skin test

2016 Analyst & Investor Day 5

Table of Contents

LOGO

 

Targeting high-risk groups for TB detection

Disease progression    TB infection and transmission

?    HIV infected ?Healthcare workers

?    Immunosuppressive therapies ?Immigrants from high

? Growing use of biologics    TB-burden countries

?    End-stage renal disease ?Prisoners

?    Children under age 5 ?Homeless

?    Elderly ?Military

Cumulative risks

Immigrants with co-morbidities

Diabetes

Tobacco use

Malnourishment

Globalization and travel

Urgent need for stricter TB testing due to fragmented landscape of risk groups

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

My patient did not know TB was preventable Tuberculosis cases in San Francisco*

500 All cases With AIDS

1980: 494 400

Latent TB infection Destructive TB disease

300

My personal experience

? Dedicated my career to fighting TB 200

? Director, TB Control in San Francisco 2010: 94? Lifelong TB educator and advocate

100

? National policy maker (incl. IGRAs) 1980: 0

2010: 4

? Leadership positions in various U.S. and international organizations

0

1980 1990 2000 2010

LTBI treatment prevents devastating individual and public health consequences

IGRA – Interferon-gamma release assay

Sample to Insight * Source: San Francisco Department of Public Health, John Blanchard/ San Francisco Chronicle

2016 Analyst & Investor Day 7

Table of Contents

LOGO

 

Classic TB screening algorithm    

TB symptom screen in high-risk person    

Yes (symptoms)     No symptoms

    TST or IGRA

Positive    Negative

Chest radiography    

TB and    Any abnormality No abnormality

other disease    

investigations     Treat for LTBI

TB elimination requires accurate testing to reduce unnecessary healthcare    costs

Source: 2014 WHO LTBI Management Guidelines

Sample to Insight LTBI – Latent TB infection     IGRA – Interferon-gamma release assay     TST – Tuberculin skin test

2016 Analyst & Investor Day 8

Table of Contents

LOGO

 

FDA-approved TB diagnostic options

Tuberculin skin test QuantiFERON-TB ELISPOT assay

PPD ESAT-6, CFP-10, TB 7.7 ESAT-6, CFP-10

Cytokine induction PPD / M. tuberculosis

specific antigen Calcineurin inhibitors:

Impaired cytokine induction

APC

T-cell

Lymphocyte-depleting agents:

T-cell depletion

End-stage renal disease: Corticosteroids:

Impaired co-stimulatory capacity Impaired T-cell / APC function

Current diagnostic aids for TB detection rely on cellular immunity

Sample to Insight APC – Antigen-presenting cell     PPD – Purified protein derivative used in tuberculin skin test (TST)

2016 Analyst & Investor Day 9

Table of Contents

LOGO

 

Tuberculin skin test (TST) QuantiFERON-TB (QFT)

?    Manual placement, reading and data entry ?Can be fully automated

?    Results affected by BCG vaccine and NTM ?Highly specific

?    Two patient visits required, high no-show rate ?Results with one patient visit

?    Significant inter-reader variability ?No inter-reader variability

?    Poor surveillance tool ?Electronic results (straight to EMR)

?    Often no quality control after initial training ?Quality-assured laboratory test(1)

TST least effective in most vulnerable: BCG-vaccinated and “hard to reach”

BCG—Bacillus Calmette-Guerin vaccine     NTM – Non-tuberculosis myobatetria EMR – Electronic medical record Sample to Insight (1)    Not available in all markets

2016 Analyst & Investor Day 10

Table of Contents

LOGO

 

Sensitivity meta-analyses QFT TST Overlapping PPDs can affect TST results

M. tuberculosis PPD Sester et al. ERJ. 2011 80% 65%

Diel et al. Chest. 2010 –

84.5% 71.5% Developed country

255

19 62

Specificity meta-analyses QFT TST 8

Diel et al. ERJ. 2011 99.4% 88.7%

35 19 2 U.S. CDC Guidelines. 2010 99% 85%

Diel et al. Chest. 2010 99.2% ND M. avium PPD M. bovis PPD

Purified Protein Derivatives (PPDs) are far from being “pure”

QuantiFERON-TB consistently shown as more specific and sensitive than TST

Sample to Insight Prasad TSK, et al. Clinical Proteonmics 2013;10:8     ND – No data     QFT – QuantifERON-TB     TST – Tuberculin skin test     PPD – Protein purified derivative

2016 Analyst & Investor Day 11

Table of Contents

LOGO

 

Current FDA-approved and CE-marked Interferon Gamma Release Assays

    QuantiFERON-TB GoldT-Spot®

Objectivity    ? No cell purification or counting?Lab worker subjectivity in cell counting

?    Spectrophotometer and software analysis

Interpretation    ? One cut-off point used worldwide?Cut-off varies by country

criteria     and in all published studies?Borderline results should be repeated

?    No borderline zone

Blood volume    ? 3 mL in total (1mL in each of 3 tubes)?6 mL minimum in lithium heparin

Assay sample    ? Whole blood?Purified PBMC – high labor component

Handling time    ? 16 hours?8 hours from collection

before processing    ? Once incubated, additional 72 hours?32 hours possible using Xtend® reagent

Scalability    ? Yes?Limited by manual workflow

QuantiFERON-TB: Leading IGRA with significant clinical and workflow benefits

Sample to Insight T-Spot is a trademark of Oxford Immunotec PBMC – Peripheral blood mononuclear cells IGRA – Interferon-gamma release assay

2016 Analyst & Investor Day 12

Table of Contents

LOGO

 

Changing perspectives on TB policy in China

2015 Lancet ID: China’s first multi-center population-based study of latent TB

Head-to-head testing in the same 21,000 people

Results: TST overestimated TB infection rates

QuantiFERON-TB showed lower latent TB prevalence in China, impact on guidelines

China study: QFT/TST and background TB by site China study: Results overview

50 QFT positive rate

41.69 Overall TB infection rate

TST positive rate

38.60 Test (% of positive tests)

40 Background TB rate

30 28.81 Tuberculin skin test 28%

19.81 19.09

20 17.37

14.77 15.50

13.47 QuantiFERON-TB Gold 18.8%

10 13.05 10.68

4.09

0

Site C Site D Site A Site B

21,000-person China study shows scalability of QuantiFERON-TB for testing

Sample to Insight Lei Gao et al, Lancet Infect Dis 2015; Feb 11. http://dx.doi.org/10.1016/S1473-3099(14)71085-0     TST – Tuberculin skin test

2016 Analyst & Investor Day 13

Table of Contents

LOGO

 

QuantiFERON-TB in New York City

Largest study ever involving QuantiFERON-TB ? 69,273 people tested (2006-2011 study)

Goal: Better estimate background prevalence of TB

Results: Positive QuantiFERON-TB data consistent with known TB risk factors – but half the rate with TST

Conclusion: IGRAs like QuantiFERON-TB are reliable for detecting TB infection

QuantiFERON-TB Gold    Tuberculin skin test

(3nd generation QFT) (n=20,066)    (Historic rate)

Positive    14% 24%

Negative    83%

Indeterminate    <1%

U.S.-born positive    9% 9%

Foreign-born positive    19% 40%

Making an impact on public health with better understanding of TB prevalence

Stennis et al, Open Forum Infect Dis. 2014 Sep; 1(2): ofu047 Published online 2014 Jul 29. doi: 10.1093/ofid/ofu047     Sample to Insight TST – Tuberculin skin test     IGRA – Interferon-gamma release assay

2016 Analyst & Investor Day 14

Table of Contents

LOGO

 

California TB control

2,170 Californians with TB

10,000 TB suspect cases

20,000 contacts to cases

million with TB infection 38 million Californians

USPSTF guidelines

IGRAs are key elements to policy development and TB elimination efforts

Sample to Insight Data provided by California Department of Public Health (2013)     IGRA – Intereron-gamma release assay     USPSTF – U.S. Preventive Services Task force

2016 Analyst & Investor Day 15

Table of Contents

LOGO

 

QuantiFERON – the leading IGRA for TB detection    

1st generation    2nd generation 3rd generation4th generation

QuantiFERON®-TB    QuantiFERON®-TB Gold QuantiFERON®-TB GoldQuantiFERON®-TB Gold Plus

(liquid antigen)    (QFT® in tube)(QFT®-Plus)

    Q4 2014: CE-IVD

2001: FDA approval    2004: FDA approval 2007: FDA approval2016: FDA submission

Measured cell-mediated    Used antigens specific for Blood collection tubes asAddition of patented CD8

immune response to same    M. tuberculosis complex incubation vessels withantigens – potential biomarker

tuberculin purified protein    organisms full automationof intracellular TB burden

derivative (PPD) used for    

TST (M. avium)    

QuantiFERON-TB Gold Plus: Developing new clinical and workflow benefits

Sample to Insight IGRA – Intereron-gamma release assay     TST – Tuberculin skin test

2016 Analyst & Investor Day 16

Table of Contents

LOGO

 

QuantiFERON-TB Gold Plus: Gaining attention in 2016 WHO TB report

CD8 and CD4 T-cell response

Current IGRA assays primarily detect a CD4

T-cell response. However, a new generation

assay, the QuantiFERON-TB Plus (QFT-

Plus, Qiagen, Hilden, Germany), has been

developed to stimulate gamma interferon

production by both CD4 and CD8 T-cells.

First results indicate that the CD8 T-cell

response may be able to identify people at

greater risk of progression to active TB.

QuantiFERON-TB Gold Plus: Potential to better identify risk for progression

Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.

Sample to Insight

Eur Respir J. 2016:ERJ-00510-02016.

2016 Analyst & Investor Day

17

Table of Contents

LOGO

 

TB remains a stealth foe and a global killer

QuantiFERON-TB changing the way the world looks at TB prevention and elimination

Leading IGRA test used to date in >30 million patients

Key clinical benefits with new QFT 4th generation test

Sample to Insight

2016 Analyst & Investor Day 18

Table of Contents

Exhibit 99.9

LOGO

 

GeneReader NGS System:

The world’s first truly complete Sample to Insight NGS system

Jonathan Arnold

Senior Director, Business Leader for Oncology Franchise, MDx Business Area

November 15, 2016

Table of Contents

LOGO

 

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section

21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including factors such as general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is currently available for marketing and sales outside the United States. The QIAGEN GeneReader® NGS System with new sequencing chemistry will be made available in the United States starting in December 2016. The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements

Sample to Insight

2016 Analyst & Investor Day

2

Table of Contents

LOGO

 

    Applied

Academia    Pharma Testing

Universal NGS

Single-cell genomics    Whole exome

Gene expression    Whole genome

Targeted resequencing    

Molecular Diagnostics

GeneReader NGS System

Clinical research

Translational medicine

Oncology

Hereditary diseases

Infectious diseases

Nucleic acid    Target LibraryNext-Data

collection &    enrichment preparationgenerationanalysisInterpretation

extraction     sequencing

Universal NGS:    Universal NGS:

QIAseq portfolio    CLC / Ingenuity / QCI

GeneReader NGS System    

QIAGEN    well-positioned across all segments of theNGS market

Sample to Insight

2016 Analyst & Investor Day

3

Table of Contents

LOGO

 

Key challenges

Simple    Seamless Cost-

workflow    bioinformatics effective

Labs want solutions to issues preventing them from realizing NGS promise

Sample to Insight

2016 Analyst & Investor Day

4

Table of Contents

LOGO

 

GeneReader NGS System: Designed to deliver actionable insights

The first complete Sample to Insight NGS solution

Sample to Insight

2016 Analyst & Investor Day 5

Table of Contents

LOGO

 

GeneReader NGS System: Key benefits and unique selling proposition

The first truly complete NGS workflow

Seamlessly integrated flexible work?ow

Delivered by a single vendor you can trust

Actionable insights

Create relevant reports

Proven gene panels and bioinformatics

Flexibility to fit your needs    Predictable costs Expertise and service

Scalable batch sizes    Price-per Insight modelGlobal team support

Continuous loading    Affordable and efficientEfficient operation help

Delivering on the promise of NGS to improve lives

Sample to Insight

2016 Analyst & Investor Day

6

Table of Contents

LOGO

 

Best-in-class consumables pull-through with flexible and transparent pricing models

Capital purchase

Flexible Price-Per-Insight pricing

Reagent rental

QIAGEN is a true NGS partner willing to share operational risk

Sample to Insight

2016 Analyst & Investor Day 7

Table of Contents

LOGO

 

Nucleic Acid Next-

Target Library Data collection & generation Interpretation enrichment preparation analysis extraction sequencing

Automation

QIAcube QIAgility QIAcube GeneRead Gene QCI QIAcube Reader Quality control RGQ

QIAxcel

Support

GeneRead Assistant Data management

GeneRead Link and LIMS

Offering everything needed from one vendor for NGS solutions

Sample to Insight

2016 Analyst & Investor Day 8

Table of Contents

LOGO

 

QIAact tumor panels: Based on clinical utility and insights

Drug labels

Clinical Trails

QIAGEN Knowledge Base

Clinical Case    Scientific

Counts    literature

Professional

External guidelines databases

Designed to deliver research-relevant insights

Sample to Insight

2016 Analyst & Investor Day

9

Table of Contents

LOGO

 

Actionable Insight Tumor Panel: Providing actionable insights    

Targeting solid tumors with    Seamless integration with QCI

Highest prevalence    to maximize scale

Greatest need for testing    

Variants associated with actionable insights    

Featuring 12 clinically actionable genes

KRAS    ERBB2

NRAS    PIK3CA

KIT    ERBB3

BRAF    ESR1

PDGFRA    RAF1

ALK    

EGFR    

Focus on validity and utility

Sample to Insight

2016 Analyst & Investor Day

10

Table of Contents

LOGO

 

Broadening system capabilities    

Expanding range of sample types    

Liquid biopsy    

Fresh and frozen tissue    

Adding test content    

Expand into lung and breast cancer    

A T G CA    

T ACG T    

Customized panel options expanding in 2017    

Enabling CNV and gene fusion detection    

Improving system capabilities    

New sequencing chemistry    

Further platform integration    

Upgrading QCI    

Expanding Sample to Insight capabilities    

Sample to Insight    

2016 Analyst & Investor Day     11

Table of Contents

LOGO

 

GeneReader NGS System roadmap    

Liquid Biopsy     New sequencingBRCA expansionCDx PartnershipsReproductive health

? cfDNA detection    chemistry Additional genes? Develop assaysDevelop reproductive

? Monitoring     FFPEhealth products

    Lung All-in-OneLiquid biopsy

    CNV, SNV, InDel

    Gene fusionsAIT FAST Panel

BRCA 1/2     BRCA expansionOncohematologyComprehensiveInfectious

SNV,     Known largeMyeloidcancer paneldiseases

InDel    rearrangementsComplement to

    RNA Seq Assaytargeted panels

Lung DNA     CNV, SNV,

SNV    InDel

CNV    Gene fusions

    Customized content development

GeneReader NGS System capabilities will continue to expand new content and new markets    

2015     2017+

Actionable Insight Tumor Panel to be broadly released with new chemistry in Q1 2017    

GeneReader NGS System: Roadmap for new features in 2017 and beyond    

Sample to Insight    

2016 Analyst & Investor Day     12

Table of Contents

LOGO

 

AMP 2016: GeneReader returning to the U.S. with new chemistry

Sample to Insight

2016 Analyst & Investor Day 13

Table of Contents

LOGO

 

New sequencing chemistry performance    data

RAS agreement study     therascreen PCR and Pyro assays

>5% RAS variant allele frequency cutoff     + (MT)–(WT)Total

+ (MT)    13013

GeneReader NGS System    –(WT) 02929

Total    132942

Sample    KRAS RAS Variant allele frequency (%)

no.    AA Change therascreen PCR/ PyroGeneReaderAlternative platform

1    G12D +207

2    G12D +3712

3    A59T 191614

4    G12D +4411

5    Q61H 141013

6    A146P 414232

7    Q61H 364126

8    Q61H 322535

9    K117N 243639

10    G13D +4415

11    G12C +3210

12    G13D +2710

13    Q61H 262623

100 % concordance between GeneReader and QIAGEN therascreen

Sample to Insight

2016 Analyst & Investor Day

14

Table of Contents

LOGO

 

Sequencing oncology market by customer

1200

$700-1,000 m

1000

800

600 $350-500 m

400

200

0

2016 2020

Clinical Lab – Routine Dx lab

CSP (Comm. Service Prov.) – Reference lab Core Lab – Sample consolidator Individual Lab – Academic

Targeting a double digit market share in the benchtop oncology NGS segment

Sample to Insight

2016 Analyst & Investor Day 15

Table of Contents

LOGO

 

GeneReader value proposition resonating extremely well

Roadmap to strengthen competitive positioning

Leveraging synergies of platform-agnostic solutions and GeneReader NGS System

Sample to Insight

2016 Analyst & Investor Day 16